Viking Therapeutics closes $632.5M public offering of 7.44M shares at $85.00

Viking Therapeutics, Inc.

Closed public offering of 7,441,650 shares at $85.00 each, including full exercise of underwriters' option for 970,650 additional shares.
Gross proceeds of approximately $632.5 million before underwriting discounts and offering expenses.
Net proceeds will fund continued development of VK2809, VK2735, VK0214 programs and general corporate purposes.
Joint book-running managers: Morgan Stanley, Leerink Partners, William Blair, Raymond James, Stifel, Truist Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.